Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis by Sahli, Rahel et al.
Sellar collision tumor involving pituitary gonadotroph adenoma
and chondroma: a potential clinical diagnosis
Rahel Sahli Æ Emanuel Christ Æ Dominique Kuhlen Æ
Olivier Giger Æ Istvan Vajtai
Published online: 17 September 2009
 Springer Science+Business Media, LLC 2009
Abstract We report on a 74-year-old male patient who
presented with progressive neuroophthalmologic symp-
toms soon after the administration of a long-acting gona-
dotropin-releasing hormone agonist for treatment of a
prostate cancer. Imaging revealed a destructively growing
and extensively calcified sellar mass inconsistent with a
pituitary adenoma. A transseptal transsphenoidal tumor
mass reduction yielded a histological diagnosis of a colli-
sion tumor comprised of a gonadotroph adenoma inter-
mingled with osteochondroma. We discuss a potential
causal relationship between the administration of the long-
acting gonadotropin-releasing hormone agonist and the
sudden appearance of the previously unsuspected sellar
lesion. Although the association of these two tumors is very
likely coincidental, the possibility of causal relationship is
addressed.
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Introduction
There is a broad differential diagnosis of clinically non-
functioning sellar mass lesions, but the overwhelming
majority of these histologically and immunophenotypically
correspond to gonadotroph pituitary adenomas. Less fre-
quent sellar tumors—among them collision tumors—may
not be identified as such preoperatively, although some
diagnostic clues (e.g., calcifications; cystic change) are
likely to argue against conventional pituitary adenoma
from the outset. We recently had the opportunity of
studying a patient with a hitherto undocumented type
of sellar collision tumor, the clinical and imaging aspects
of which nevertheless allowed for its composite character
to be postulated preoperatively.
Case report
A 74-year-old male patient received a first dose of a long
acting gonadotropin-releasing hormone agonist (GnRH-
agonist, Gosereline 3.6 mg) for treatment of a recently
detected prostate cancer. Subsequently he developed severe
headache accompanied by nausea and vomiting, followed
by the occurrence of a right third cranial nerve palsy.
Laboratory evaluation including endocrine testing was
only notable for a considerably increased serum level of
follicle-stimulating hormone (FSH; 21.3 IU/l; normal range
1–12 IU/l) (Table 1). Magnetic resonance imaging (MRI)
and computed tomography (CT) disclosed a partially calci-
fied destructively growing skull base tumor of 29 9 27 9
25 mm originating from the sella turcica with invasion of the
cavernous, sphenoid, and ethmoid sinuses (Fig. 1).
In the face of massive tumor bulk and the compro-
mise of perilesional anatomy, a limited exploration via
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transseptal transsphenoidal route was opted for to provide
histological diagnosis along with rapid chiasmal decom-
pression. Ultimately, only the calcified part of the tumor
(approximate volume 1 ml, 2.5 9 1.4 9 0.3 cm) was
amenable to resection. Postoperative ophthalmological
examination nevertheless indicated improvement of the
visual field. The endocrine evaluation showed partial
pituitary insufficiency and a persistently increased level of
FSH. A subsequent conventional fractionated radiotherapy
(54 Gy) was administered.
Histologically, the specimen consisted of a composite
adenomatous–chondromatous lesion. The first component,
a chromophobe pituitary adenoma was composed of sheets
of epithelial cells with clear cytoplasm. Rather nondescript
in itself, this tumor was remarkable for its being focally
colonized by osteoclastic giant cells. Gonadotropic phe-
notype of tumor cells was evidenced by immunostaining
for FSH and a-subunit. The second component, an orga-
noid association of trabecular bone and hyaline cartilage
was reminiscent of osteochondroma, as it occurs in less
unconventional locations. Intimately associated with the
chondromatous moiety throughout, adenoma cells were
alternately seen either encircling islands of cartilage or
expanding, plug-like, osseous trabeculae supporting chon-
droid matrix (Fig. 2).
Discussion
Sellar collision tumors—the simultaneous occurrence of
two or more distinct primary tumors—are remarkably
uncommon [1]. They consist mainly of a pituitary adenoma
and a Rathke’s cleft cyst [1–3], while double adenomas [1,
4, 5] occur less frequently. Further documented examples
include pituitary adenoma coexisting with craniopharyn-
gioma [6], arachnoid cyst [7], colloid cyst [8] or epider-
moid cyst [9], Schwannoma [10], plasmocytoma [11], and
meningioma [12]. Sellar collision without an adenomatous
component is exceedingly uncommon [13].
To our knowledge, we present the first example of a
sellar collision tumor involving gonadotrophic adenoma
along with a benign cartilage-producing moiety with fea-
tures of chondroma. Chondrogenic neoplasms of the sellar
region, both benign and malignant, are very uncommon
[14–18]. Chondromas tend to frequent the cartilagineous
growth plate of long bones, a structure the sphenoid bone is
devoid of [19]. Although chondromas have no pathogno-
monic radiologic features, CT shows irregular and mottled
calcification in 60% and local bone destruction occurs in
50% of intracranial chondromas [14].
Whereas sellar collision tumors are mostly diagnosed
histologically, the sequence of events in connection with
the extensive calcification could have allowed for this
presumptive preoperative diagnosis in the case presented
herein.
First, if GnRH-agonists trigger symptoms of rapid sellar
enlargement as acute headache, ophthalmoplegia and
decreased visual acuity, the underlying pathology most
likely is a gonadotroph pituitary adenoma. Possible
mechanisms are the long-standing stimulatory effect on
tumoral gonadotropin secretion (Table 1) and an increase
in cellular volume, precipitating the compression of sellar
Table 1 Laboratory results at admission and after operation and
radiotherapy
Normal range At admission Postoperative and
postradiotherapy
Cortisol nmol/L 521
TSH 0.2–0.4 mU/L 0.43 0.97
FT4 9–26 pmol/L 15 12.7
FSH 1–12 IU/L 21.3 17.3
LH 2–12 IU/L 7.0 \0.1
Total
testosterone
6.3–26.3 nmol/L 20 0.43
Prolactin 4–19 lg/L 9.2 3.5
IGF-1 64–188 ng/ml 149 72
Fig. 1 MRI shows a destructively growing, gadolinium-enhancing skull base tumor in the sellar region, displacing the optic chiasm (a) with
extensive calcification in CT scan (b) as well as bone erosion and infiltration of the adjacent sinuses (c)
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structures. As in the presented case, this clinical syndrome
occurs even in the absence of an actual hemorrhage or
infarction [20].
Although potentially life-threatening, pituitary apoplexy
is rare and pretreatment testing would not be cost effective.
Nevertheless, attention to pituitary disease prior to injec-
tion and during follow up is required.
Second, excepting the proverbial ‘‘pituitary stone’’ in an
occasional prolactinoma, more than minute calcifications
are not expected to be seen on imaging of pituitary ade-
nomas [21]. If present, it is legitimate to entertain the
possibility of a nonadenomatous sellar tumor. Calcifica-
tions are a standard fixture of adamantinomatous cranio-
pharyngiomas. Likewise, sellar meningiomas may harbor
Fig. 2 Microscopic features of composite adenomatous-chondroma-
tous lesion obtained at resection. (a) shows chromophobe pituitary
adenoma composed of sheets of epithelial cells with clear cytoplasm.
Rather nondescript in itself, this tumor was remarkable for its being
focally colonized by osteoclastic giant cells (arrows). Gonadotropic
phenotype of tumor cells is evidenced by immunostaining for FSH (b)
and a-subunit (c). Invasion of bone (b–arrow) as well as respiratory
mucosa of sphenoid sinus (c) is appreciated. Intimately associated
with the chondromatous moiety throughout, adenoma cells were
alternately seen either encircling islands of cartilage (d) or expanding,
plug-like (e), osseous trabeculae supporting chondroid matrix. The
organoid association of trabecular bone and hyaline cartilage (f) is
reminiscent of osteochondroma, as it occurs in less unconventional
locations. (g) shows cartilagineous mass to broadly encroach upon
sphenoid sinus mucosa, while adenoma cells (h) tend to display
infiltrative growth. Photomicrographs not labeled otherwise represent
hematoxylin and eosin staining. Immunohistochemical reactions (b
and c) were visualized with polymer-bound horseradish peroxidase
(Envision ? ; Dako, Glostrup, Denmark) and 3, 30-diaminobenzidine.
Original magnifications: a–d and g 9200; e, f, h 9100
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psammoma bodies [22]. In this context, two exceptional
case reports on metaplastic ossification in a somatotroph
cell adenoma and a gonadotroph cell adenoma have to be
mentioned [23, 24].
Considering the high frequency of gonadotroph adeno-
mas and the ‘‘first ever’’ character of the constellation
documented here, the coexistence of a gonadotroph ade-
noma and a chondroma is very likely coincidental.
Some circumstantial evidence of a possible relationship
between these two entities might be inferred from the
observation that human pituitary adenoma cells exert pro-
liferative and growth-promoting activity on chondrocytes
via secretion of fibroblast growth factor (b-FGF) [25]. It is
tempting to speculate that b-FGF secretion, which in turn is
stimulated by pituitary tumor transforming gene (PTTG),
may have contributed to the progression of the chondroma
by a paracrine effect in the present case [26].
In addition to b-FGF, locally produced bone morpho-
genetic proteins (BMPs) and Activins, both members of the
transforming growth factor b superfamily, may also be
involved in the development of gonadotroph pituitary
adenomas [27] and osteochondromas [28] as well.
Recently, there has been growing awareness of both
nonadenomatous and combined neoplasms of the pituitary
[1]. As illustrated here, exact nosological diagnosis of such
lesions ultimately requires microscopic study. We never-
theless conclude that, in some cases, the unexpected or
contradictory character of clinical and imaging findings
may be apt to suggest the possibility of a collision tumor
prior to the biopsy procedure.
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